Aug 5, 2026 07:00AM
Jul 8, 2026 07:01AM
Jul 8, 2026 07:00AM
Jun 25, 2026 07:00AM
Jun 5, 2026 07:00AM
Jun 5, 2026 07:00AM
May 12, 2026 07:00AM Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
May 5, 2026 07:00AM
May 4, 2026 07:00AM
May 4, 2026 07:00AM
Apr 20, 2026 07:00AM
Apr 9, 2026 07:00AM
Mar 12, 2026 07:00AM
Mar 2, 2026 04:06PM Seres Therapeutics names Richard Kender as interim CEO
Mar 2, 2026 04:05PM
Feb 12, 2026 07:01AM
Feb 12, 2026 07:00AM
Jan 6, 2026 07:02AM
Jan 6, 2026 07:00AM
Nov 24, 2025 07:00AM
Nov 5, 2025 07:00AM Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Oct 30, 2025 07:00AM
Oct 29, 2025 07:00AM
Oct 14, 2025 07:00AM
Oct 14, 2025 07:00AM
Sep 24, 2025 06:28AM
Sep 23, 2025 07:00AM
Sep 23, 2025 07:00AM Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Aug 27, 2025 07:00AM
Aug 6, 2025 07:00AM
Jul 22, 2025 07:07AM
Jul 22, 2025 07:01AM
Jul 22, 2025 07:00AM
May 27, 2025 07:02AM
May 27, 2025 07:00AM Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
May 8, 2025 05:06AM
May 7, 2025 07:00AM
Apr 29, 2025 07:00AM
Apr 23, 2025 07:00AM
Mar 13, 2025 07:00AM
Mar 4, 2025 07:00AM
Mar 3, 2025 07:00AM Seres Therapeutics (MCRB) Receives Feedback From FDA on SER-155
Mar 3, 2025 07:00AM
Jan 16, 2025 07:01AM
Jan 16, 2025 07:00AM
Jan 9, 2025 07:00AM
Dec 16, 2024 07:00AM
Dec 9, 2024 07:06AM
Dec 9, 2024 07:00AM FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Nov 22, 2024 07:00AM

327,796 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All